Dexamethasone dimenhidrinate

Phase 3Small molecule

YYeditepe University Hospital

Dexamethasone dimenhidrinate is one of 13 small molecule programs targeting Hypospadias. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypospadiasNot yet recruiting

HypospadiasPhase 3

Not yet recruiting

Competition

Competitive Landscape

14 competitors in Hypospadias

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

3 2

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

1 3

Ketalar

AAultman Health Foundation

Approved

1 4

Naropin

FFresenius Kabi USA, LLC

Approved

1 5

Celestone

Advil

Tylenol

Oxycontin

Atropen

FFresenius Kabi Taiwan Ltd.

Approved

—10

Dexamethasone dimenhidrinate

YYeditepe University Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nausea and vomiting4 trials

Prevention of Postoperative Nausea and Vomiting

Completed·YYeditepe University Hospital·Phase 4·NCT02382146·60 enrolled

Prevention of Nausea and Vomiting in Patients After Surgery

Completed·YYeditepe University Hospital·Phase 4·NCT02021851·67 enrolled

Dexamethasone and Ondansetron Versus Placebo for Postoperative Nausea and Vomiting

Completed·HHopital Foch·Phase 4·NCT01876290·122 enrolled

Show 1 more trial

Comparison of Three Different Prophylactic Treatments of Postoperative Nausea and Vomiting (PONV) in Children

Completed·—·Phase 4·NCT01434017·300 enrolled

Hypospadias1 trial

Preventative Effect of Combining Dexamethasone with Ondansetron on Postoperative Nausea, Vomiting and Shivering in Children Undergoing Caudal Anesthesia on Hypospadias Surgery

Not yet recruiting·—·Phase 4·NCT06747975·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Dexamethasone dimenhidrinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexamethasone dimenhidrinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexamethasone dimenhidrinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yeditepe University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: YYeditepe University Hospital

Dexamethasone dimenhidrinate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nausea and vomiting4 trials

Hypospadias1 trial

References

Drug Info

Quick Facts

Related News